Study of Substance P, Renin and Aldosterone in chronic liver disease in Egyptian children

Journal of Tropical Pediatrics

Volumn 51, Issue 5, 2005, Pages 320-323

  El Raziky, M S ^a   Gohar, N ^b   El Raziky, M ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALDOSTERONE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN GLUCURONIDE; CREATININE; RENIN; SUBSTANCE P;

ARTICLE; CHILD; CHILDHOOD DISEASE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE MARKER; EGYPT; GLYCOGEN STORAGE DISEASE; HUMAN; HUMAN TISSUE; PLASMA RENIN ACTIVITY; PROGNOSIS; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ALDOSTERONE; CASE-CONTROL STUDIES; CHILD; CHRONIC DISEASE; EGYPT; FEMALE; HUMANS; LIVER DISEASES; MALE; RENIN; SUBSTANCE P;

EID: 27144466377     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmi060     Document Type: Article

References (16)

1. Alam I, Bass NM, Bachetti P, Gee L. Hepatic tissue endothelin-1 level on chronic liver disease correlated with disease severity and ascites. Amer J Gastroentrol 2000; 95: 199-203.
2. Lee FY, Lin HC, Tsai VT, Chang FY. Plasma Substance P level in patients with liver cirrhosis: Relation-ship to systemic and portal hemodynamics. Amer J Gastroentrol 1997; 92: 2080-84.
3. Lee CP, Lee FY, Chang FY. Role of Substance P in the pathogenesis of spider angioma on patients with nonalcoholic liver cirrhosis. Amer J Gastroentrol 1999; 94: 502-07.
4. Conrado M, Fernardez R, Jeusu P. Plasma levels of Substance P in liver cirrhosis: Relation to the activation of vasopressor system and urinary sodium excretion. Hepatology 1995; 21: 35-40.
5. Heide H, Ernest A, Kurt L, Herbert L. Substance P is markedly increased in plasma of patients with hepatic coma. Lancet 1994; 3: 480-83.
6. Selena H, Pierangelo G. Substance P. Int J Biochem Cell Biol 2001; 33: 555-76.
7. Mischielsen PP, Smith T, Pelckmans PA. Hemodynamic changes in portal hypertension: New insight in the pathogenesis and clinical impactions. Acta Gastroentrolagica Belgica 1994; 8: 201-12.
8. Teppei K, Tadashi M, Yoshiharu C, Hajime N. Substance P, vasoactive intestinal polypeptide and gastrin catabolism in canine liver and kidney. Dig Dis Sci 1992; 37: 1661-65.
9. Kannourakis G. Glycogen storage disease. Semin Hematol 2002; 39: 103-06.
10. Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. Rev Endocr Metab Disord 2003; 4: 95-102.
11. Hop CE, Wang Y, Kumar S. Identification of metabolites of a Substance P (neurokinin 1 receptor) antagonist in rat hepatocytes and rat plasma. Drug Metab Dispos 2002; 30: 937-43.
12. Chu CJ, Lee FY, Chang FY. Hyperdynamic circulation, role of Substance P and relationship to nitric oxide. Scand J Gastroentrol 1997; 32: 841-46.
13. Uemura M, Tsuji T, Kikuchi E, Matsumura M. Increased plasma level of Substance P and disturbed water excretion in patients with liver cirrhosis. Scand J Gastroenterol 1998; 33: 860-66.
14. Chen CY, Lu CL, Chang FY, Huang YS. The impact of chronic hepatitis B viral infection on gastrointestinal motility. Eur J Gastroentrol Hepatol 2000; 12: 995-1000.
15. Fredrico R, Carlos M, Roberto J. Platelet cytosolic calcium, peripheral hemodynamics, and vasodilatory peptide in liver cirrhosis. Gastroentology 1993; 105: 863-67.
16. Kojima H, Tsujimoto T, Uemura M. Significance of increased plasma adrenomedullin concentration in patients with cirrhosis. J Hepatol 1998; 28: 840-46.